Forecast: Sales of Pharmaceutical Preparations Affecting Neoplasms, The Endocrine System and Metabolic Diseases in the US

Sales of pharmaceutical preparations impacting neoplasms, the endocrine system, and metabolic diseases in the US are projected to exhibit moderate growth from 2024 to 2028. In 2023, actual sales were $28.5 billion, indicating a stable market with forecasts predicting sales reaching approximately $29.293 billion by 2028. Year-on-year growth is anticipated to be gradual, with percentage increases lingering around 0.6% to 0.7% annually. The compound annual growth rate (CAGR) over the five-year period from 2024 to 2028 is expected to be steady, reflecting consistent demand in pharmaceutical innovations for these therapeutic areas.

Future trends to watch for:

• Advancements in personalized medicine and precision therapy, potentially boosting market growth.
• Regulatory changes and healthcare reimbursement policies impacting drug pricing.
• Development of biosimilars and their role in competitiveness and cost-efficiency.
• Technological innovations in drug discovery and delivery systems enhancing market dynamics.